Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 23 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 10106616

    Antagonist antibodies to human prolactin receptor (PRLR)

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted
  2. US 10106610

    Antibodies comprising chimeric constant domains

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted
  3. US 10081670

    Human antibodies to Ebola virus glycoprotein

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 25, 2018 · Expires Sep 20, 2038

    granted
  4. US 10076571

    Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 18, 2018 · Expires Sep 13, 2038

    granted
  5. US 10077311

    Human antibodies to GFR alpha3 and methods of reducing pain associated with GFR alpha3-related diseases

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 18, 2018 · Expires Sep 13, 2038

    granted
  6. US 10070632

    Rodents having a humanized TMPRSS gene

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 11, 2018 · Expires Sep 6, 2038

    granted
  7. US 10070631

    Rodents having a humanized TMPRSS gene

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 11, 2018 · Expires Sep 6, 2038

    granted
  8. US 10072076

    Human antibodies to NAv1.7

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 11, 2018 · Expires Sep 6, 2038

    granted
  9. US 10072086

    Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 11, 2018 · Expires Sep 6, 2038

    granted
  10. US 10066017

    Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 4, 2018 · Expires Aug 30, 2038

    granted
  11. US 10059771

    Methods for treating nasal polyposis by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 28, 2018 · Expires Aug 23, 2038

    granted
  12. US 10047152

    Human antibodies to fel D1 and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 14, 2018 · Expires Aug 9, 2038

    granted
  13. US 10047153

    Human antibodies to Fel d1 and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 14, 2018 · Expires Aug 9, 2038

    granted
  14. US 10047160

    Anti-EGFRvIII antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 14, 2018 · Expires Aug 9, 2038

    granted
  15. US 10023644

    Antigen-binding proteins that activate the leptin receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted
  16. US 10023641

    Anti-TIE2 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted
  17. US 10023642

    Anti-PDGFR-beta antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted
  18. US 10023916

    Markers of tumor cell response to anti-cancer therapy

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted
  19. US 10023654

    Anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted
  20. US 10015953

    Non-human animals having a humanized cluster of differentiation 47 gene

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted
  21. US 10011647

    IL-33 antagonists and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted
  22. US 10005834

    Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 26, 2018 · Expires Jun 21, 2038

    granted
  23. US 10000564

    Methods of treating an inflammatory condition or sensitivity to an allergen with anti-IL-33 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 19, 2018 · Expires Jun 14, 2038

    granted
  24. US 9986724

    Genetically modified non-human animals and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 5, 2018 · Expires May 31, 2038

    granted